|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Washington Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Seattle Genetics, Inc.
| | | Phone: | (425) 527-4000 | Fax: | (425) 527-4001 | Year Established: | 1998 | Employees: | 1200 | Ticker: | SGEN | Exchange: | NASDAQ | Main Contact: | Peggy Pinkston, Executive Director, Corporate Communications | | Other Contacts: | Roger D. Dansey, M.D., CMO Darren Cline, Executive VP, Commercial Elaine Waller, PharmD, Executive VP, Regulatory Affairs Christopher Pawlowicz, Executive VP, Human Resources Jonathan Drachman, M.D., CMO & Executive VP, R&D Jean I. Liu, J.D., General Counsel, Executive VP, Legal Affairs Vaughn Himes, Ph.D., CTO Todd E. Simpson, CFO Eric L. Dobmeier, COO Clay B. Siegall, Ph.D., President & CEO
| | Company Description | Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells.
The company’s lead product, ADCETRIS® (brentuximab vedotin), is a CD30-targeted ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available in more than 55 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 70 ongoing clinical trials in CD30-expressing malignancies. Seattle Genetics is also advancing vadastuximab talirine (SGN-CD33A; 33A), an ADC that is expected to advance into a phase 3 trial for acute myeloid leukemia in 2016. Beyond ADCETRIS and 33A, the company is developing a robust pipeline of clinical-stage programs, including denintuzumab mafodotin (SGN-CD19A; 19A), SGN-LIV1A, ASG-15ME, ASG-22ME, SGN-CD70A and SEA-CD40.
Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer.. | |
|
|
|